

Applicants: Ng et al.
U.S.S.N.: 08/670,119
Filed: June 25, 1996
Page 2

OFFICIAL

FAX RECEIVED

JAN 26 1999

GROUP 1600

AMENDMENT

In the Specification:

Please amend the Specification as follows:

At page 42, line 14, please delete "5P" and insert -- 5g --;

At page 42, please delete lines 15 to 26;

At page 43, after line 20, insert

-- Figures 6e to 6g show the results of a control experiment in the same rat.

Administration of saline resulted in an unexpected transient increase in blood pressure from 150/100 to 180/100, with no change in heart rate, before stabilising to baseline values (Figure 6e).

Administration of peptide vehicle had no significant effect on heart rate, but lowered blood pressure marginally from 150/100 to 140/80 (Fig. 6g). Subsequent administration of 5 µg/Kg phenylephrine showed no diminution of effect and reduced heart rate to 240 beats/min with blood pressure rising to 180/140 (Fig. 6f). --

In the Claims:

Please amend claims 18, 32, 35, 36, and 62-64, as follows:

18. (Twice Amended) A method of treating, in a mammal, a disorder for which administration of an antagonist of an integral membrane protein having at least one transmembrane domain is indicated, said method comprising administering to the mammal an effective amount of an antagonist peptide [comprising] consisting essentially of at least four consecutive amino acid residues from the amino acid sequence of said at least one transmembrane domain or a conservative amino acid substitution variant of said peptide to specifically inhibit the activity of the integral membrane protein.